The cell surface glycoprotein Trop-2 is commonly overexpressed in carcinomas and represents an exceptional antigen for targeted therapy. Here, we provide evidence that surface Trop-2 expression is functionally connected with an epithelial phenotype in breast and prostate cell lines and in patient tumor samples. We further show that Trop-2 expression is suppressed epigenetically or through the action of epithelial-to-mesenchymal transition transcription factors and that deregulation of Trop-2 expression is linked with cancer progression and poor patient prognosis. Moreover, our data suggest that the cancer plasticity-driven intratumoral heterogeneity in Trop-2 expression may significantly contribute to response and resistance to therapies targeting Trop-2-expressing cells.

Center of Biomolecular and Cellular Engineering International Clinical Research Center St Anne's University Hospital Brno Brno Czech Republic

Department of Clinical and Molecular Pathology Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacky University Olomouc Olomouc Czech Republic

Department of Cytokinetics Institute of Biophysics of the Czech Academy of Sciences Brno Czech Republic

Department of Experimental Biology Faculty of Science Masaryk University Brno Czech Republic

Department of Urology Faculty of Medicine and Dentistry Palacky University Olomouc Olomouc Czech Republic

Citace poskytuje Crossref.org

Orthotopic model for the analysis of melanoma circulating tumor cells

ATF2 loss promotes tumor invasion in colorectal cancer cells via upregulation of cancer driver TROP2

TACSTD2 upregulation is an early reaction to lung infection

Skp2 and Slug Are Coexpressed in Aggressive Prostate Cancer and Inhibited by Neddylation Blockade

Trop2: Jack of All Trades, Master of None

High Skp2 expression is associated with a mesenchymal phenotype and increased tumorigenic potential of prostate cancer cells